左卡尼汀联合血液透析在尿毒症患者中的应用效果及对同型半胱氨酸、炎症因子的影响  

Application Effects of Levocarnitine Combining with Hematodialysis on Uremia Patients and Influences on Homocysteine and Inflammatory Factors

作　　者：赵鹏飞[1] 孙茹 郭鸿[1] ZHAO Peng-fei;SUN Ru;GUO Hong(Department of nephropathy,Affiliated Hospital of Shanxi University of Traditional Chinese medicine,Sh anxi Taiyuan 030024,China)

机构地区：[1]山西中医学院附属医院肾病科,山西太原030024

出　　处：《临床医药文献电子杂志》2017年第86期16978-16980,共3页Electronic Journal of Clinical Medical Literature

摘　　要：目的探讨血液透析(HD)联合左卡尼汀应用于尿毒症治疗对患者炎症因子、同型半胱氨酸(Hcy)产生的影响及总疗效。方法从2016.01~2017.03期间在本院接受透析治疗的尿毒症患者中随机选取60例分为参照组(HD治疗,n=30)、观察组(HD+左卡尼汀,n=30),回顾性分析患者炎症因子、Hcy变化情况及总体疗效。结果治疗后,观察组超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、白细胞介素-6(IL-6)水平及Hcy水平均有明显降低,有对比参照组有显著差异(P<0.05);观察组治疗后血红蛋白含量有明显增加,对比参照组差异显著(P<0.05);观察、参照二组不良反应为6.67%VS 26.67%,差异对比显著(P<0.05)。结论同时对尿毒症患者行血液透析、左卡尼汀治疗,能够使患者Hcy水平得到明显降低,促进机体炎症状态得到更大程度改善,提高总体疗效。Objective To discuss influences and overall curative effects of Hemodialysis(HD)combining with levocarnitine on uremia patients’inflammatory factors and homocysteine(HCY);Methods From January 2016 to March 2017,60 uremia patients who accepted HD in our hospital were selected at random and they were divided into the control group(HD treatment,n=30)and observation group(HD+levocarnitine,n=30)to retrospectively analyze their inflammatory factors,HCY changing situations and overall curative effects.Results After treatment,hypersensitivity C-reactive protein(HS-CRP),tumor necrosis factorα(TNF-α)and interleukin-6(IL-6)level and HCY level were significantly reduced.There was the significant difference by comparing with the control group(P<0.05).The untoward effects of the observation group and the control group were 6.67%and 26.67%,respectively.There was the significant difference(P<0.05).Conclusion Simultaneous utilization of HD and levocarnitine for uremia patients can significantly reduce HCY level of paients and promote inflammatory state to be improved and enhance overall curative effects.

关 键 词：尿毒症 血液透析 左卡尼汀 炎症因子 同型半胱氨酸 

分 类 号：R692.5[医药卫生—泌尿科学]